By DrBicuspid Staff

July 11, 2016 -- Vigilant Biosciences has raised $5 million to commercialize OncAlert, its oral cancer detection test.

Vigilant has received $12.5 million in total funding, including most recently a round of $5 million in Series B funding. The proceeds will be used for the international commercialization of OncAlert and to continue the company's research and development efforts.

Copyright © 2016

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking